Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

September 13, 2019September 13, 2019

New Agreement in Scotland Grants CF Patients Access to Orkambi and Symkevi

News

A new agreement will give people in Scotland with cystic fibrosis access to the CF combination treatments Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) through the country’s health system, according to ... Read more

September 10, 2019September 10, 2019

Drexel Study to Look at Tailored ‘Talk’ Therapy in Helping Ease Depression and Anxiety in CF Patients

cystic fibrosis, News

How well Acceptance and Commitment Therapy (ACT), or tailored “talk” therapy that can be delivered via telemedicine, helps people with cystic fibrosis (CF) cope with mental health issues will ... Read more

September 5, 2019September 5, 2019

Claire’s Place Foundation Glow Ride Will Include Virtual Riders This Year

cystic fibrosis, News

Claire’s Place Foundation is preparing for its 5th Annual Glow Ride event to raise money to support families affected by cystic fibrosis. The 3.4 mile-long bike ride will take place ... Read more

August 29, 2019August 29, 2019

A. Fumigatus Fungus Linked to Worse Respiratory Quality of Life in People with CF, Study Finds

News

The presence of the fungus Aspergillus fumigatus is linked to lower respiratory-related quality of life in people with cystic fibrosis (CF), a study has found. The study, “The presence ... Read more

August 23, 2019August 23, 2019

Path BioAnalytics Acquires Cavosonstat From Laurel Therapeutics for Further Study

News

Path BioAnalytics (PBA), a biotechnology company based in North Carolina, has licensed the rights to further develop cavosonstat (N91115), a targeted therapy for cystic fibrosis (CF), from the Chinese company Laurel Therapeutics. Cavosonstat is a ... Read more

August 9, 2019September 18, 2019

’65_RedRoses’ Event, Tracing Life of Woman with CF, Will Support Transplant Research in Canada

cystic fibrosis, News

A 10th anniversary screening of the documentary “65_RedRoses” will take place on Sunday, Sept. 8, at the Vancouver Playhouse Theatre to raise funds for the Transplant Research Foundation of ... Read more

July 30, 2019July 31, 2019

Proteostasis Begins Dosing in Phase 2 Trial of 3 CF Investigational Therapies

cystic fibrosis, News

The first patient has been dosed in a Phase 2 clinical trial testing Proteostasis Therapeutics‘s combinations of three investigational therapies for cystic fibrosis (CF), the company announced. The three ... Read more

July 23, 2019September 4, 2019

Vertex Asks FDA to Approve 1st Triple Combo for CF – Elexacaftor, Tezacaftor and Kalydeco

cystic fibrosis, News

Vertex Pharmaceuticals is asking the U.S. Food and Drug Administration to approve a first triple combination therapy — elexacaftor (VX-445) plus tezacaftor, and ivacaftor (Kalydeco) — to treat cystic fibrosis (CF) ... Read more

July 17, 2019August 28, 2019

Pregnancy in CF Women With Poor Lung Function Not Linked to Pulmonary Decline, Study Shows

cystic fibrosis, News

Poorer lung function in pregnant women with cystic fibrosis (CF) is associated with a lower birth weight for offspring, and a higher likelihood of cesarean section — but not ... Read more

July 10, 2019August 26, 2019

AzurRx BioPharma Launches Phase 2 Trial Testing MS1819-SD Combined With PERT for EPI

cystic fibrosis, News

AzurRx BioPharma has initiated a Phase 2 clinical trial testing its oral capsule MS1819-SD, combined with standard porcine pancreatic enzyme replacement therapy (PERT), in people with cystic fibrosis (CF) ... Read more

Pin It on Pinterest